| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 8 | 2024 | 141 | 3.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 20 | 2024 | 1201 | 2.830 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2024 | 833 | 2.030 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2024 | 541 | 1.600 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 164 | 1.510 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 184 | 1.500 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2023 | 28 | 1.420 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 50 | 1.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 144 | 1.200 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 177 | 1.140 |
Why?
|
| Graft vs Host Disease | 10 | 2024 | 542 | 1.070 |
Why?
|
| Hematologic Neoplasms | 5 | 2024 | 286 | 0.960 |
Why?
|
| Lymphoma, Follicular | 3 | 2020 | 30 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1255 | 0.790 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 294 | 0.790 |
Why?
|
| Primary Myelofibrosis | 2 | 2020 | 51 | 0.750 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.700 |
Why?
|
| Antigens, CD20 | 1 | 2020 | 37 | 0.700 |
Why?
|
| Aged | 32 | 2024 | 19878 | 0.670 |
Why?
|
| Transplantation Conditioning | 8 | 2020 | 324 | 0.650 |
Why?
|
| Middle Aged | 34 | 2024 | 26939 | 0.620 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 103 | 0.610 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 299 | 0.610 |
Why?
|
| SEER Program | 1 | 2019 | 202 | 0.600 |
Why?
|
| Rituximab | 5 | 2024 | 158 | 0.600 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 38 | 0.590 |
Why?
|
| Transplantation, Homologous | 5 | 2019 | 666 | 0.580 |
Why?
|
| Pyrazoles | 6 | 2024 | 305 | 0.570 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 42 | 0.560 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 140 | 0.550 |
Why?
|
| Standard of Care | 1 | 2018 | 130 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1143 | 0.540 |
Why?
|
| Lymphoma | 4 | 2023 | 323 | 0.520 |
Why?
|
| Humans | 59 | 2025 | 125156 | 0.510 |
Why?
|
| Sulfonamides | 4 | 2024 | 271 | 0.510 |
Why?
|
| Pyrimidines | 7 | 2024 | 373 | 0.500 |
Why?
|
| Recurrence | 6 | 2024 | 1421 | 0.480 |
Why?
|
| Adult | 29 | 2024 | 29645 | 0.470 |
Why?
|
| Doxorubicin | 3 | 2024 | 290 | 0.470 |
Why?
|
| Medicare | 1 | 2018 | 426 | 0.460 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1694 | 0.430 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 6603 | 0.430 |
Why?
|
| Retrospective Studies | 23 | 2024 | 16334 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 539 | 0.410 |
Why?
|
| Cyclophosphamide | 6 | 2024 | 417 | 0.400 |
Why?
|
| Male | 33 | 2024 | 61508 | 0.380 |
Why?
|
| Survival Analysis | 6 | 2021 | 1508 | 0.360 |
Why?
|
| Female | 33 | 2024 | 66787 | 0.360 |
Why?
|
| Treatment Outcome | 16 | 2024 | 12392 | 0.350 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1276 | 0.350 |
Why?
|
| Allografts | 2 | 2023 | 191 | 0.340 |
Why?
|
| Etoposide | 3 | 2024 | 115 | 0.340 |
Why?
|
| Neoplasms | 2 | 2024 | 2794 | 0.340 |
Why?
|
| Prednisone | 3 | 2024 | 276 | 0.330 |
Why?
|
| Vincristine | 3 | 2024 | 193 | 0.330 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 1727 | 0.320 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2019 | 11 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 118 | 0.300 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 483 | 0.290 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 272 | 0.290 |
Why?
|
| Survival Rate | 4 | 2019 | 2064 | 0.270 |
Why?
|
| Boron Compounds | 2 | 2024 | 31 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 725 | 0.260 |
Why?
|
| Adenine | 3 | 2024 | 103 | 0.260 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 259 | 0.260 |
Why?
|
| Young Adult | 8 | 2021 | 9059 | 0.250 |
Why?
|
| Glycine | 2 | 2024 | 168 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 152 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 2 | 2019 | 337 | 0.230 |
Why?
|
| Genetics, Population | 1 | 2025 | 188 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 38 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 650 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 125 | 0.200 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2019 | 11 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 27 | 0.200 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 900 | 0.190 |
Why?
|
| Prognosis | 3 | 2019 | 4642 | 0.190 |
Why?
|
| Piperidines | 2 | 2020 | 208 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 319 | 0.190 |
Why?
|
| Budesonide | 1 | 2021 | 19 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 197 | 0.180 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 108 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 15 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 80 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 119 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 68 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 100 | 0.170 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 93 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2019 | 13 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 170 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 202 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 293 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 64 | 0.150 |
Why?
|
| Melphalan | 1 | 2018 | 49 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 16 | 0.150 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 38 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 63 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 129 | 0.140 |
Why?
|
| Etanercept | 1 | 2017 | 40 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 365 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1035 | 0.140 |
Why?
|
| Disease Management | 2 | 2018 | 527 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2019 | 192 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2022 | 680 | 0.140 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 50 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2017 | 340 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 62 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 389 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2018 | 1179 | 0.130 |
Why?
|
| Remission Induction | 3 | 2023 | 300 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2019 | 385 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5177 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 635 | 0.120 |
Why?
|
| United States | 5 | 2024 | 10916 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 2821 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1169 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1241 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 726 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 325 | 0.110 |
Why?
|
| Plasmacytoma | 1 | 2013 | 7 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 731 | 0.100 |
Why?
|
| Cytokines | 1 | 2018 | 1289 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 225 | 0.090 |
Why?
|
| Insurance, Health | 2 | 2024 | 139 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 2 | 2024 | 29 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2013 | 167 | 0.090 |
Why?
|
| Adolescent | 4 | 2023 | 19356 | 0.080 |
Why?
|
| Outpatients | 2 | 2024 | 253 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 294 | 0.080 |
Why?
|
| Nitriles | 2 | 2020 | 146 | 0.080 |
Why?
|
| Methotrexate | 2 | 2024 | 336 | 0.080 |
Why?
|
| Busulfan | 2 | 2020 | 45 | 0.080 |
Why?
|
| Vidarabine | 2 | 2020 | 80 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2020 | 98 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2430 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 512 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 3071 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2248 | 0.070 |
Why?
|
| Incidence | 3 | 2019 | 3146 | 0.070 |
Why?
|
| Latin America | 1 | 2025 | 92 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 61 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 74 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 309 | 0.060 |
Why?
|
| Unrelated Donors | 1 | 2024 | 82 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 275 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 173 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 122 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 522 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 122 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 69 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 164 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 281 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 255 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2025 | 760 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 702 | 0.050 |
Why?
|
| Neutropenia | 1 | 2023 | 200 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 537 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 641 | 0.040 |
Why?
|
| DNA Topoisomerase IV | 1 | 2020 | 12 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 316 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 389 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2020 | 22 | 0.040 |
Why?
|
| Software | 1 | 2025 | 683 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 469 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6333 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 354 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 295 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 257 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 47 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 581 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 173 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 70 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 881 | 0.040 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genome, Human | 1 | 2025 | 1272 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 797 | 0.030 |
Why?
|
| Fever | 1 | 2019 | 298 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 369 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2018 | 525 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10310 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1196 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2636 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 535 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1120 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1697 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 499 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 400 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2064 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1942 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1055 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1101 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3348 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1361 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2013 | 55 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1433 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4820 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 17635 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 34224 | 0.010 |
Why?
|